ABSTRACT

Bulky tumor is another important prognostic factor with performance status and serum LDH levels in patients with high grade, extra-nodal headneck NHL. It is a parameter that should be evaluated during the treatment plan.

The mean follow-up was 32.64 months. Overall and disease-free survival, and 2-year survival rates were 75.73 and 74.89 months, and 78% and 67%, respectively. Poor performance status, elevated serum LDH levels or the presence of bulky disease were found to have a negative impact on both overall and disease-free survival. Statistically significant differences were determined according to overall and disease-free survival in favor of the low-moderate risk groups. Poor performance status, elevated serum LDH level and bulky disease were determined to affect survival both alone and together.

Between 1997 and 2004, 33 patients with high-grade extranodal head-neck NHL were treated. The female to male ratio was 13:20 and median age was 48 years. The tumor was located in the Waldeyer ring in 29 patients; in 19 of these, it was in the tonsillar region. B symptom(s) and elevated serum LDH levels were present in 14 and 12 patients, respectively. The phenotype was diffuse large cell in 30 patients. A median of 6 cycles of chemotherapy (CHOP for 30 patients and CEOP for 3 patients) was administered to all patients followed by a median 40 Gy in-volved-field radiotherapy. Survival was analyzed by creating three different risk groups (low, moderate or high risk) including the parameters of bulky tumor (tumor diameter more than 6 cm), age, LDH level, performance status and stage.

Torotroapeatlely analyze the prognastik factors on survival in high grate head and neck non hodgkin lymphomas.